Donald Mctavish
It has been suggested that older and cheaper oral drugs for type 2 diabetes may be just as effective at controlling glycemia and improving lipid profiles as newer agents. Metformin, discovered in 1929 and on the U.S. market since the 1950s, appears to have the most favorable risk-benefit profile, investigators have written in the Annals of Internal Medicine. Why has no better product been developed since 1929?